BDBM50155809 (R)-4-[1-(3-5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl-propionyl)-piperidin-4-yl]-3-(5,6,7,8-tetrahydro-quinolin-3-yl)-butyric acid::CHEMBL187014

SMILES OC(=O)C[C@@H](CC1CCN(CC1)C(=O)CCc1ccc2CCCNc2n1)c1cnc2CCCCc2c1

InChI Key InChIKey=PQYGSGMXFJNDPV-UHFFFAOYSA-N

Data  14 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 14 hits for monomerid = 50155809   

TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50155809((R)-4-[1-(3-5,6,7,8-Tetrahydro-[1,8]naphthyridin-2...)
Affinity DataIC50: 4.70E+3nMAssay Description:Inhibitory concentration for biotinylated fibrinogen binding to immobilized alpha IIb beta-3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50155809((R)-4-[1-(3-5,6,7,8-Tetrahydro-[1,8]naphthyridin-2...)
Affinity DataIC50: 5.00E+4nMAssay Description:Inhibitory concentration for biotinylated fibrinogen binding to immobilized alpha IIb beta-3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-5(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50155809((R)-4-[1-(3-5,6,7,8-Tetrahydro-[1,8]naphthyridin-2...)
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta5 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50155809((R)-4-[1-(3-5,6,7,8-Tetrahydro-[1,8]naphthyridin-2...)
Affinity DataIC50: 4.70E+3nMAssay Description:Inhibitory concentration for biotinylated fibrinogen binding to immobilized alpha IIb beta-3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-5(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50155809((R)-4-[1-(3-5,6,7,8-Tetrahydro-[1,8]naphthyridin-2...)
Affinity DataIC50: 8.70nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta5 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50155809((R)-4-[1-(3-5,6,7,8-Tetrahydro-[1,8]naphthyridin-2...)
Affinity DataIC50: 2.70nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-5(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50155809((R)-4-[1-(3-5,6,7,8-Tetrahydro-[1,8]naphthyridin-2...)
Affinity DataIC50: 2.20E+3nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta5 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50155809((R)-4-[1-(3-5,6,7,8-Tetrahydro-[1,8]naphthyridin-2...)
Affinity DataIC50: 26nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50155809((R)-4-[1-(3-5,6,7,8-Tetrahydro-[1,8]naphthyridin-2...)
Affinity DataIC50: 26nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-5(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50155809((R)-4-[1-(3-5,6,7,8-Tetrahydro-[1,8]naphthyridin-2...)
Affinity DataIC50: 7.80nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta5 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-5(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50155809((R)-4-[1-(3-5,6,7,8-Tetrahydro-[1,8]naphthyridin-2...)
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta5 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50155809((R)-4-[1-(3-5,6,7,8-Tetrahydro-[1,8]naphthyridin-2...)
Affinity DataIC50: 52nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50155809((R)-4-[1-(3-5,6,7,8-Tetrahydro-[1,8]naphthyridin-2...)
Affinity DataIC50: 4.70E+3nMAssay Description:Inhibitory concentration for biotinylated fibrinogen binding to immobilized alpha IIb beta-3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50155809((R)-4-[1-(3-5,6,7,8-Tetrahydro-[1,8]naphthyridin-2...)
Affinity DataIC50: 1.20nMAssay Description:Inhibitory concentration for human vitronectin binding to immobilized alphaV-beta3 integrinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed